{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:10:13Z","timestamp":1791897013747,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005869","name":"University of Fribourg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005869","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To evaluate the different present and future therapeutic \u03b2-lactam\/\u03b2-lactamase inhibitor (BL\/BLI) alternatives, namely aztreonam-avibactam, imipenem-relebactam, meropenem-vaborbactam, cefepime-zidebactam, cefepime-taniborbactam, meropenem-nacubactam, and sulbactam-durlobactam against clinical isolates showing reduced susceptibility or resistance to cefiderocol in Enterobacterales,\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      , and\n                      <jats:italic>Pseudomonas aeruginosa.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      MIC values of aztreonam, aztreonam-avibactam, cefepime, cefepime-taniborbactam, cefepime-zidebactam, imipenem, imipenem-relebactam, meropenem, meropenem-vaborbactam, meropenem-nacubactam, sulbactam-durlobactam, and cefiderocol combined with a BLI were determined for 67, 9, and 11 clinical Enterobacterales,\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      or\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      isolates, respectively, showing MIC values of cefiderocol being \u22651 mg\/L. If unavailable, the respective \u03b2-lactam breakpoints according to EUCAST were used for BL\/BLI combinations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For Enterobacterales, the susceptibility rates for aztreonam, cefepime, imipenem, and meropenem were 7.5%, 0%, 10.4%, and 10.4%, respectively, while they were much higher for cefepime-zidebactam (91%), cefiderocol-zidebactam (91%), meropenem-nacubactam (71.6%), cefiderocol-nacubactam (74.6%), and cefiderocol-taniborbactam (76.1%), as expected. For\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      isolates, the higher susceptibility rates were observed for imipenem-relebactam, cefiderocol-zidebactam, and meropenem-vaborbactam (56% for all combinations). For\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      isolates, lower susceptibility rates were observed with commercially or under development BL\/BLI combos; however, a high susceptibility rate (70%) was found for sulbactam-durlobactam and when cefiderocol was associated to some BLIs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Zidebactam- and nacubactam-containing combinations showed a significant in vitro activity against multidrug-resistant Enterobacterales clinical isolates with reduced susceptibility to cefiderocol. On the other hand, imipenem-relebactam and meropenem-vaborbactam showed the highest susceptibility rates against\n                      <jats:italic>P. aeruginosa<\/jats:italic>\n                      isolates. Finally, sulbactam-durlobactam and cefiderocol combined with a BLI were the only effective options against\n                      <jats:italic>A. baumannii<\/jats:italic>\n                      tested isolates.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10096-023-04732-4","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T01:04:43Z","timestamp":1702515883000},"page":"339-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility\/resistance to cefiderocol: which are the best present and future therapeutic alternatives?"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-5576","authenticated-orcid":false,"given":"Christophe","family":"Le Terrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-1622","authenticated-orcid":false,"given":"Patrice","family":"Nordmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5160-5286","authenticated-orcid":false,"given":"Laurent","family":"Poirel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"issue":"Suppl 7","key":"4732_CR1","doi-asserted-by":"publisher","first-page":"S521","DOI":"10.1093\/cid\/ciz824","volume":"69","author":"P Nordmann","year":"2019","unstructured":"Nordmann P, Poirel L (2019) Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria. Clin Infect Dis 69(Suppl 7):S521\u2013S528","journal-title":"Clin Infect Dis"},{"key":"4732_CR2","unstructured":"World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017 Available at: \"http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf.%20Accessed%2024%20July%202023\""},{"issue":"5","key":"4732_CR3","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1128\/AAC.50.5.1633-1641.2006","volume":"50","author":"J Quale","year":"2006","unstructured":"Quale J, Bratu S, Gupta J, Landman D (2006) Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 50(5):1633\u20131641","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"4732_CR4","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1128\/AAC.00574-09","volume":"53","author":"JM Rodr\u00edguez-Mart\u00ednez","year":"2009","unstructured":"Rodr\u00edguez-Mart\u00ednez JM, Poirel L, Nordmann P (2009) Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53(11):4783\u20134788","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4732_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1128\/MMBR.67.4.593-656.2003","volume":"67","author":"H Nikaido","year":"2003","unstructured":"Nikaido H (2003) Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 67(4):593\u2013656","journal-title":"Microbiol Mol Biol Rev"},{"issue":"1","key":"4732_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.00042-16","volume":"30","author":"LY Hsu","year":"2017","unstructured":"Hsu LY, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah PA (2017) Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin Microbiol Rev 30(1):1\u201322","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"4732_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ (2022) Infectious Diseases Society of America 2022 Guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis 75(2):187\u2013212","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4732_CR8","doi-asserted-by":"publisher","first-page":"e0003922","DOI":"10.1128\/aac.00039-22","volume":"66","author":"L Poirel","year":"2022","unstructured":"Poirel L, Ortiz de la Rosa JM, Sadek M, Nordmann P (2022) Impact of acquired broad-spectrum \u03b2-lactamases on susceptibility to cefiderocol and newly developed \u03b2-lactam\/\u03b2-lactamase inhibitor combinations in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 66(4):e0003922","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"4732_CR9","doi-asserted-by":"publisher","first-page":"e0087721","DOI":"10.1128\/AAC.00877-21","volume":"65","author":"L Poirel","year":"2021","unstructured":"Poirel L, Sadek M, Nordmann P (2021) Contribution of PER-type and NDM-type \u03b2-lactamases to cefiderocol resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 65(10):e0087721","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4732_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10096-021-04397-x","volume":"41","author":"L Poirel","year":"2022","unstructured":"Poirel L, Sadek M, Kusaksizoglu A, Nordmann P (2022) Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants. Eur J Clin Microbiol Infect Dis 41(4):677\u2013680","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"4732_CR11","doi-asserted-by":"publisher","first-page":"106917","DOI":"10.1016\/j.ijantimicag.2023.106917","volume":"62","author":"X Vuillemin","year":"2023","unstructured":"Vuillemin X, Da Silva M, Bour M, Landon C, Pl\u00e9siat P, Jeannot K (2023) cefiderocol activity is compromised by acquired Extended Spectrum-Oxacillinases in Pseudomonas aeruginosa. Int J Antimicrob Agents 62(3):106917","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"4732_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10096-022-04526-0","volume":"42","author":"M Sadek","year":"2023","unstructured":"Sadek M, Le Guern R, Kipnis E, Gosset P, Poirel L, Dessein R, Nordmann P (2023) Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 42(1):61\u201366","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl 1","key":"4732_CR13","first-page":"S649","volume":"7","author":"M Takemura","year":"2020","unstructured":"Takemura M, Yamano Y, Matsunaga Y, Ariyasu M, Echols R, Nagata TD (2020) 1266. Characterization of shifts in minimum inhibitory concentrations during treatment with cefiderocol or comparators in the phase 3 CREDIBLE-CR and APEKS-NP studies. Open Forum. Infect Dis 7(Suppl 1):S649\u2013S650","journal-title":"Infect Dis"},{"issue":"1","key":"4732_CR14","doi-asserted-by":"publisher","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","volume":"34","author":"D Yahav","year":"2020","unstructured":"Yahav D, Giske CG, Gr\u0101matniece A, Abodakpi H, Tam VH, Leibovici L (2020) New \u03b2-lactam-\u03b2-lactamase inhibitor combinations. Clin Microbiol Rev 34(1):e00115\u2013e00120","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"4732_CR15","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1473-3099(23)00069-5","volume":"23","author":"C Le Terrier","year":"2023","unstructured":"Le Terrier C, Gruenig V, Fournier C, Nordmann P, Poirel L (2023) NDM-9 resistance to taniborbactam. Lancet Infect Dis 23(4):401\u2013402","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"4732_CR16","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/jac\/dkad210","volume":"78","author":"C Le Terrier","year":"2023","unstructured":"Le Terrier C, Nordmann P, Buchs C, Di DYW, Rossolini GM, Stephan R, Castanheira M, Poirel L (2023) Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: a One Health concern. J Antimicrob Chemother 78(9):2382\u20132384","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"4732_CR17","doi-asserted-by":"publisher","first-page":"e0033923","DOI":"10.1128\/aac.00339-23","volume":"67","author":"C Le Terrier","year":"2023","unstructured":"Le Terrier C, Nordmann P, Freret C, Seigneur M, Poirel L (2023) Impact of acquired broad spectrum \u03b2-lactamases on susceptibility to novel combinations made of \u03b2-lactams (aztreonam, cefepime, meropenem, and imipenem) and novel \u03b2-lactamase inhibitors in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 67(7):e0033923","journal-title":"Antimicrob Agents Chemother"},{"key":"4732_CR18","volume-title":"Relative inhibitory activities of the broad-spectrum \u00df-lactamase inhibitor taniborbactam against metallo-\u00df-lactamases","author":"C Le Terrier","year":"2023","unstructured":"Le Terrier C, Viguier C, Nordmann P, Poirel L (2023) Relative inhibitory activities of the broad-spectrum \u00df-lactamase inhibitor taniborbactam against metallo-\u00df-lactamases. Antimicrob Agents Chemother Accepted"},{"issue":"10","key":"4732_CR19","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1093\/jac\/dkac241","volume":"77","author":"C Lasarte-Monterrubio","year":"2022","unstructured":"Lasarte-Monterrubio C, Fraile-Ribot PA, V\u00e1zquez-Ucha JC, Cabot G, Guijarro-S\u00e1nchez P, Alonso-Garc\u00eda I, Rumbo-Feal S, Gal\u00e1n-S\u00e1nchez F, Beceiro A, Arca-Su\u00e1rez J, Oliver A, Bou G (2022) Activity of cefiderocol, imipenem\/relebactam, cefepime\/taniborbactam and cefepime\/zidebactam against ceftolozane\/tazobactam- and ceftazidime\/avibactam-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 77(10):2809\u20132815","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"4732_CR20","doi-asserted-by":"publisher","first-page":"e0167621","DOI":"10.1128\/AAC.01676-21","volume":"66","author":"JC V\u00e1zquez-Ucha","year":"2022","unstructured":"V\u00e1zquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-S\u00e1nchez P, Ovia\u00f1o M, \u00c1lvarez-Fraga L, Alonso-Garc\u00eda I, Arca-Su\u00e1rez J, Bou G, Beceiro A, GEMARA-SEIMC\/REIPI Enterobacterales Study Group (2022) Assessment of activity and resistance mechanisms to cefepime in combination with the novel \u03b2-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing Enterobacterales. Antimicrob Agents Chemother 66(2):e0167621","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4732_CR21","doi-asserted-by":"publisher","first-page":"e0128122","DOI":"10.1128\/aac.01281-22","volume":"67","author":"JA Karlowsky","year":"2023","unstructured":"Karlowsky JA, Hackel MA, Wise MG, Six DA, Uehara T, Daigle DM, Cusick SM, Pevear DC, Moeck G, Sahm DF (2023) In vitro activity of cefepime-taniborbactam and comparators against clinical isolates of Gram-negative bacilli from 2018 to 2020: results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrob Agents Chemother 67(1):e0128122","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4732_CR22","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/jac\/dkad061","volume":"78","author":"C Le Terrier","year":"2023","unstructured":"Le Terrier C, Nordmann P, Sadek M, Poirel L (2023) In vitro activity of cefepime\/zidebactam and cefepime\/taniborbactam against aztreonam\/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates. J Antimicrob Chemother 78(5):1191\u20131194","journal-title":"J Antimicrob Chemother"},{"key":"4732_CR23","unstructured":"ClinicalTrials.gov (2022). Study of cefepime-zidebactam (FEP-ZID) in complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04979806. Accessed 1 Nov 2023"},{"key":"4732_CR24","unstructured":"ClinicalTrials.gov (2022). Safety and efficacy study of cefepime\/VNRX-5133 in patients with complicated urinary tract infections (CERTAIN-1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03840148.\u00a0Accessed 1 Nov 2023"},{"key":"4732_CR25","unstructured":"ClinicalTrials.gov (2022). A study to investigate the intrapulmonary lung penetration of nacubactam in healthy participants. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03182504.\u00a0Accessed 1 Nov 2023"},{"key":"4732_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jgar.2022.05.011","volume":"30","author":"J Findlay","year":"2022","unstructured":"Findlay J, Poirel L, Bouvier M, Nordmann P (2022) In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance. J Glob Antimicrob Resist 30:445\u2013450. https:\/\/doi.org\/10.1016\/j.jgar.2022.05.011","journal-title":"J Glob Antimicrob Resist"},{"issue":"9","key":"4732_CR27","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"KS Kaye","year":"2023","unstructured":"Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O'Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D (2023) Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis 23(9):1072\u20131084","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"4732_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.diagmicrobio.2019.03.003","volume":"94","author":"MA Hackel","year":"2019","unstructured":"Hackel MA, Tsuji M, Yamano Y, Echols R, Karlowsky JA, Sahm DF (2019) Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth. Diagn Microbiol Infect Dis 94(4):321\u2013325","journal-title":"Diagn Microbiol Infect Dis"},{"key":"4732_CR29","unstructured":"EUCAST (2023) Breakpoint tables for interpretation of MICs and zone diameters. Version 13:1.\u00a0https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_13.1_Breakpoint_Tables.pdf. Accessed 1 Nov 2023"},{"issue":"1","key":"4732_CR30","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/jac\/dkac360","volume":"78","author":"C Le Terrier","year":"2022","unstructured":"Le Terrier C, Nordmann P, Poirel L (2022) In vitro activity of aztreonam in combination with newly developed \u03b2-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-\u03b2-lactamases. J Antimicrob Chemother 78(1):101\u2013107","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"4732_CR31","doi-asserted-by":"publisher","first-page":"e01659","DOI":"10.1128\/AAC.01659-20","volume":"64","author":"M Sadek","year":"2020","unstructured":"Sadek M, Juhas M, Poirel L, Nordmann P (2020) Genetic features leading to reduced susceptibility to aztreonam-avibactam among metallo-\u03b2-lactamase-producing Escherichia coli isolates. Antimicrob Agents Chemother 64(12):e01659\u2013e01620","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"4732_CR32","doi-asserted-by":"publisher","first-page":"dlaa081","DOI":"10.1093\/jacamr\/dlaa081","volume":"2","author":"T Sato","year":"2020","unstructured":"Sato T, Ito A, Ishioka Y, Matsumoto S, Rokushima M, Kazmierczak KM, Hackel M, Sahm DF, Yamano Y (2020) Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study. JAC Antimicrob Resist 2(3):dlaa081","journal-title":"JAC Antimicrob Resist"},{"issue":"4","key":"4732_CR33","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1128\/AAC.01529-07","volume":"52","author":"TA Davies","year":"2008","unstructured":"Davies TA, Shang W, Bush K, Flamm RK (2008) Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 52(4):1510\u20131512","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4732_CR34","doi-asserted-by":"publisher","first-page":"e02165","DOI":"10.1128\/AAC.02165-19","volume":"64","author":"PA Fraile-Ribot","year":"2020","unstructured":"Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofi\u00f1o E, S\u00e1nchez-Diener I, Cortes-Lara S, L\u00f3pez-Causap\u00e9 C, Cabot G, Bou G, Mart\u00ednez-Mart\u00ednez L, Oliver A, GEMARA-SEIMC\/REIPI Pseudomonas Study Group (2020) Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic \u03b2-lactam-resistant mutants. Antimicrob Agents Chemother 64(2):e02165\u2013e02119","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4732_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12866-023-02864-3","volume":"23","author":"DW Hilbert","year":"2023","unstructured":"Hilbert DW, DeRyke CA, Motyl M, Hackel M, Young K (2023) Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020. BMC Microbiol 23(1):165","journal-title":"BMC Microbiol"},{"issue":"11","key":"4732_CR36","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1093\/jac\/dkv239","volume":"70","author":"DM Livermore","year":"2015","unstructured":"Livermore DM, Mushtaq S, Warner M, Woodford N (2015) Activity of OP0595\/\u03b2-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing \u03b2-lactamases. J Antimicrob Chemother 70(11):3032\u20133041","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"4732_CR37","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/jac\/dkw593","volume":"72","author":"DM Livermore","year":"2017","unstructured":"Livermore DM, Mushtaq S, Warner M, Vickers A, Woodford N (2017) In vitro activity of cefepime\/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother 72(5):1373\u20131385","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04732-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-023-04732-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04732-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T16:38:59Z","timestamp":1706373539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-023-04732-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["4732"],"URL":"https:\/\/doi.org\/10.1007\/s10096-023-04732-4","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}